
Owens & Minor, Inc. Hits New 52-Week Low at $3.76
2025-11-03 16:58:54Owens & Minor, Inc. has reached a new 52-week low, reflecting significant challenges within the company. With a market capitalization of USD 416 million, it shows troubling financial metrics, including a negative return on equity and high debt levels, raising concerns about its long-term viability in the Pharmaceuticals & Biotechnology sector.
Read More
Owens & Minor, Inc. Hits New 52-Week Low at $4.35
2025-10-13 17:27:39Owens & Minor, Inc. has hit a new 52-week low, reflecting a challenging year with a significant stock price decline. Financial metrics show a low P/E ratio and concerning indicators such as negative Return on Equity and a high Debt to Equity ratio, highlighting ongoing valuation and profitability issues.
Read MoreIs Owens & Minor, Inc. technically bullish or bearish?
2025-09-20 19:07:58As of 5 August 2025, the technical trend for Owens & Minor, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators supporting this view including bearish MACD readings on both the weekly and monthly charts, bearish moving averages on the daily timeframe, and a bearish KST on both weekly and monthly periods. Additionally, the Bollinger Bands and OBV are showing mildly bearish signals. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -57.54% versus the S&P 500's 12.22%, and a one-year return of -64.90% compared to 17.14% for the benchmark....
Read MoreIs Owens & Minor, Inc. overvalued or undervalued?
2025-09-20 17:41:52As of 5 May 2023, the valuation grade for Owens & Minor, Inc. has moved from expensive to risky, indicating a shift in perception regarding its market value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 6, an EV to EBITDA of 4.76, and a PEG ratio of 0.14, which suggests limited growth prospects relative to its price. In comparison to peers, Owens & Minor has a higher P/E ratio than Pacific Biosciences of California, Inc., which has a P/E of -0.6779, highlighting a relative overvaluation. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -57.54% compared to the index's 12.22%. This stark contrast reinforces the notion that Owens & Minor, Inc. is currently overvalued in the market....
Read More





